Patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
Fuente : http://www.eurekalert.org/pub_releases/2014-01/uoc...
Fuente : http://www.eurekalert.org/pub_releases/2014-01/uoc...